An Experimental Obesity Pill Mimics Gastric Bypass Surgery

The drug is based on the research conducted in MIT, Giovanni Traverso, a gastroenterologist and mechanical engineer and Robert Langer, a chemical engineer who has launched more than two dozen biotech companies.

Two people invented the process while working on the development of the liquid drugs that could be given to children. They soon realized that they could make this temporary synthetic coating less accessible, either to increase the absorption or slow it. This subsequent ability applied as obesity treatment.

“This material is a thing that you will take as capsules or liquid, but the next day it is gone due to the natural turnover of our mucosal surface on the GI tract,” says Traverso. He and Langer cuffed Sintis with Dada in 2022. He compares it with this coating to stick to the rock or the bottom of the sea with the oyster and other shellfish.

In the results of the syntice declared, the drug was directly supplied through a tube to the small intestine so that the researchers could check that the polymer coating was formed as expected. A tablet form has already been tested between pigs and dogs, and Cinters planned to test it in future human studies.

In rats, the drug produces a consistent 1 percent weekly weight loss during the six -week study period while saves 100 percent of the thin muscle mass.

In the first-human pilot study of nine participants, the drug was safe without any adverse effects. The tissue samples taken from the gut were made to ensure that the coating was made and the body was cleared within 24 hours. The study was not designed to determine weight loss, but blood tests showed that after giving drugs, the glucose layer and “appetite hormone” enclosure were low and laptin levels, an appetite hormone levels were high.

“When nutrition is redirected to the intestine after nutrition, you are activating the paths that lead to satisfaction, energy consumption and overall healthy, sustainable weight loss,” said Dhanda.

Searchs in animals indicate the possibility of drugs to lose weight without compromising the muscles mass, one of the concerns with current GLP -1 drug. Although in general, weight loss is related to numerous health benefits, there is Growing Proof The kind of rigid weight loss that GLP -1S induces the strict weight loss can also reduce the mass of fat muscle.

Louis Aeron, a metabolism of metabolic research at Well -Colonel Medical College and Professor of metabolism, says that GLP -1 is wildly popular, but they may not be right for everyone. He predicts that there will be many drugs for obesity in the distant future and will be more personal for treatment. “I think the compound of the syntis perfectly fits as treatment that can be used early it is one of the things you can use as the first line drug,” he said. Aaron serves as the company’s clinical advisor.

Professor Vladimir Kushnir of Medicine and the director of Bariatric Endoscopy at the University of Washington of St. Louis, who is not involved in Sintes, says that the information of the primary pilot is encouraged, but it is hard to make any decisions from such small research. He hopes that the drug will feel full of people, but there may be some side effects like gastric bypass surgery. “My expectation is that it is some digestive side effects like flower swelling and abdominal cramping, as well as some possible diarrhea and nausea after once more research has turned into a larger study,” he said.

The first day of this fancy strategy, but if it is proven to be effective, it can one day be an alternative to GLP -1 drug or add -on drug.